Bionano Genomics, Inc. provides genome analysis software solutions. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight. The company also provides Saphyr and Bionano compute servers; and NxClinical which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; EpiPanelDx PLUS, a genetic testing panel for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures; PGx test, which identifies over 60 alleles in 11 genes. The company was founded in 2003 and is headquartered in San Diego, California.
Depending on the exchange, the stock ticker may vary. For instance, on exchange Bionano Genomics stocks are traded under the ticker 2Y30.STU.
Is Bionano Genomics stock price growing?▼
2Y30.STU stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Bionano Genomics has showed a +0% increase.
When is the next Bionano Genomics earnings date?▼
Bionano Genomics is going to release the next earnings report on May 13, 2026.
What were Bionano Genomics earnings last quarter?▼
2Y30.STU earnings for the last quarter are -2 EUR per share, whereas the estimation was -2.13 EUR resulting in a +6.26% surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does Bionano Genomics have?▼
As of April 11, 2026, the company has 98 employees.
In which sector is Bionano Genomics located?▼
Bionano Genomics operates in the Health & Wellness sector.
When did Bionano Genomics complete a stock split?▼
Bionano Genomics has not had any recent stock splits.
Where is Bionano Genomics headquartered?▼
Bionano Genomics is headquartered in San Diego, United States.